Cutler Group LP Spero Therapeutics, Inc. Call Options Transaction History

Cutler Group LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Jan 18, 2022	SELL	$13.09 - $18.77 $7,854 - $11,262	-600 Closed	0 $0
Q3 2021 Oct 26, 2021	BUY	$13.03 - $19.51 $2,606 - $3,902	200 Added 50.0%	600 $0
Q2 2021 Jul 19, 2021	SELL	$12.22 - $15.79 $34,216 - $44,212	-2,800 Reduced 87.5%	400 $0
Q1 2021 Apr 26, 2021	SELL	$13.23 - $21.48 $17,199 - $27,924	-1,300 Reduced 28.89%	3,200 $10,000
Q4 2020 Jan 21, 2021	SELL	$11.65 - $22.07 $32,620 - $61,796	-2,800 Reduced 38.36%	4,500 $34,000
Q3 2020 Oct 27, 2020	BUY	$8.96 - $14.12 $57,344 - $90,368	6,400 Added 711.11%	7,300 $20,000
Q2 2020 Jul 22, 2020	BUY	$7.27 - $14.18 $6,543 - $12,762	900 New	900 $5,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $40.7M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.